At present, the most commonly used marker of LIHC detection is AFP, although it has a certain predictive effect on the occurrence of disease, but for small liver cancer (<3 cm) were low, and 52% of small liver cancer patients were negative for AFP.[6] The emergence of molecular targeted therapy has the possibility to expand and supplement LIHC treatment methods. The gene discussed is AFP; the disease is liver cancer.